Search

Selected EMA news

March 2025New medicines recommended for approval
Lynozyfic (linvoseltamab) 
Treatment of refractory multiple myeloma (a cancer of the bone marrow)
New information on approved medicines 
Calquence (acalabrutinib) - new indication
Treatment of blood cancer

Columvi (glofitamab) - new indication
Treatment of blood cancer

Darzalex (daratumumab) - change of indication
Treatment…

Read more

EHA-SWG Scientific Meeting on Integrated Cell Tracking in Oncohematology: Diagnosis, Targeted Therapy and Residual Disease

November 10-11, 2022 | Bordeaux, France

Meeting Chairs:
MC Béné, Nantes University
G Zini, Università Cattolica S.

Read more

EHA Research Mobility Grants

The call for applications is currently closed

EHA strives to develop the career of young scientists by supporting mobility and facilitating a visit to a research group in another institute.

Read more

Recommendation for hematologists in COVID-19 crisis

Recommendations for hematologists in COVID-19 crisis
COVID-19, caused by SARS-CoV-2, is expected to be a devastating infection in patients with active cancer. It should be taken seriously and managed rigorously without jeopardizing the curative chance of individual cancer patients.

Read more

YoungEHA featured in the European Medical Journal!

As part of a series of interviews conducted at this year’s EHA congress in Amsterdam, the European Medical Journal has published their highly insightful discussions with three distinct members: Professor Shai Izraeli, Professor Barbara Bain, and YoungEHA’s very own Dr…

Read more